Real-time Intervention for Suicide Risk Reduction
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Evan M Kleiman, Ph.D.
- Phone Number: 8484458123
- Email: ekleiman@fas.harvard.edu
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Recruiting
- Massachusetts General Hospital
-
Contact:
- Jeff C Huffman, MD
- Email: jhuffman@partners.org
-
Principal Investigator:
- Jeff C Huffman, MD
-
Sub-Investigator:
- Kate H Bentley, PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- A recent suicide attempt or serious suicidal ideation (i.e., ideation with at least 70% intent or a suicide plan with access to lethal means),
- The ability to speak and write English fluently, access to an internet-capable smartphone (e.g., an iPhone or Android phone)
- Providing at least one collateral contact in cases where the investigators cannot reach the participant.
Exclusion criteria:
- The presence of any factor that impairs an individual's ability to comprehend and effectively participate in the study including:
- An inability to speak or write English fluently
- The presence of gross cognitive impairment due to florid psychosis, intellectual disability, dementia, or acute intoxication.
- The presence of extremely agitated or violent behavior.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Ecological Momentary Intervention
This group will receive three intervention prompts and three assessment prompts on their smartphone each day.
|
Content of this intervention is based on pre-established transdiagnostic protocols for addressing the negative emotion associated with suicidal thoughts and behaviors.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in momentary levels of self-reported distress
Time Frame: Through study completion (duration of inpatient stay + 4 weeks post-discharge)
|
Assessed via smartphone assessments
|
Through study completion (duration of inpatient stay + 4 weeks post-discharge)
|
|
Change in momentary levels of physiological distress
Time Frame: Through study completion (duration of inpatient stay + 4 weeks post-discharge)
|
Skin conductance (assessed with wearable device)
|
Through study completion (duration of inpatient stay + 4 weeks post-discharge)
|
|
Change in momentary levels of suicidal thinking
Time Frame: Through study completion (duration of inpatient stay + 4 weeks post-discharge)
|
Assessed via smartphone assessments
|
Through study completion (duration of inpatient stay + 4 weeks post-discharge)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Evan Kleiman, Harvard University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IRB18-1813
- R34MH113757-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.